VIA
JNCE

Vident Investment Advisory’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Vident Investment Advisory’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-133,825
Closed -$2.75M – 990
2018
Q1 		$2.75M Buy
133,825
+36,359
+37% +$807K 0.11% 263
2017
Q4 		$1.24M Buy
97,466
+26,628
+38% +$391K 0.06% 343
2017
Q3 		$1.1M Buy
70,838
+2,146
+3% +$30.3K 0.06% 354
2017
Q2 		$964K Buy
+68,692
New +$1.47M 0.08% 318

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vident Investment Advisory's JNCE Position: Q2 2018 in Review

Vident Investment Advisory sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2018, closing a stake of 133,825 shares — an estimated $2.75M sold.

Vident Investment Advisory first reported a position in JNCE in Q2 2017 and held it in 4 quarters. The position peaked at $2.75M in Q1 2018. 83 funds tracked by Wall St. Rank hold JNCE as of Q2 2018.

  • Vident Investment Advisory reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Vident Investment Advisory sold 133,825 Jounce Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $2.75M.
  • Vident Investment Advisory first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
  • Vident Investment Advisory's Jounce Therapeutics, Inc. Common Stock position peaked at $2.75M in Q1 2018.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.